Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control.
Speranza L, di Porzio U, Viggiano D, de Donato A, Volpicelli F. · 2021
Read Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control. by Speranza L, di Porzio U, Viggiano D, de Donato A, Volpicelli F. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8066851.txt.
Introduction
Speranza and co-authors review dopamine as the neuromodulator behind lasting synaptic change, reward, and movement. Dopamine shapes motor control, mood, and the drive to repeat rewards. It also tunes higher mental functions. When its signaling fails, the fallout is severe. Parkinson's disease, schizophrenia, and addiction all trace back to it.
The review follows dopamine through two forms of synaptic plasticity. Long-term potentiation and long-term depression both bend under its hand. The authors cover these effects across cortical and deep brain areas. Dendritic spines, the tiny seats of synapses, get close attention. There dopamine sits between the motor and cognitive systems. Three diseases anchor the discussion throughout. Parkinson's disease, vascular dementia, and schizophrenia show what broken tuning costs. The picture is of one molecule with many levers.
Catalog record
| CREATOR | Speranza L, di Porzio U, Viggiano D, de Donato A, Volpicelli F. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 80 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control By Luisa Speranza, Umberto di Porzio, Davide Viggiano, Antonio de Donato, Floriana Volpicelli, Jérôme Baufreton Published in: Cells DOI: 10.3390/cells10040735 ABSTRACT Abstract Dopamine (DA) is a key neurotransmitter involved in multiple physiological functions including motor control, modulation of affective and emotional states, reward mechanisms, reinforcement of behavior, and selected higher cognitive functions. Dysfunction in dopaminergic transmission is recognized as a core alteration in several devastating neurological and psychiatric disorders, including Parkinson’s disease (PD), schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD) and addiction. Here we will discuss the current insights on the role of DA in motor control and reward learning mechanisms and its involvement in the modulation of synaptic dynamics through different pathways. In particular, we will consider the role of DA as neuromodulator of two forms of synaptic plasticity, known as long-term potentiation (LTP) and long-term depression (LTD) in several cortical and subcortical areas. Finally, we will delineate how the effect of DA on dendritic spines places this molecule at the interface between the motor and the cognitive systems. Specifically, we will be focusing on PD, vascular dementia, and schizophrenia. Keywords: dopamine, reward, motor control, synaptic plasticity, LTP, LTD, schizophrenia, Parkinson’s disease, vascular dementia 1. INTRODUCTION In the mammalian brain, the dopaminergic (DAergic) systems play a central role in controlling movement, hormone release, emotional balance, reward, odor discrimination and vision. DAergic neurons are anatomically and functionally heterogeneous, located in the telencephalon, [dispersed within the glomerular layer of the olfactory blub (field A16; [1]) and the amacrine cell population of the retina (field A17; [2]), in the diencephalon where it negatively regulates the production of prolactin (hypothalamic arcuate nucleus, area A12, [3] and sub-parafascicular thalamic nucleus, area A11), which innervate the superior olivary complex and the inferior colliculus in the brain stem where it is supposed to regulate auditory processing (area 13, [4,5]). The most numerous contingent of DAergic neurons, about 70%, resides in the ventral midbrain (mDAergic) to form three distinct nuclei, the substantia nigra (SN, A9), divided into pars reticulata (SNpr) and pars compacta (SNpc), the ventral tegmental area (VTA, A10) and the retrorubric nucleus (A8). The development of mDAergic neurons in vivo is a highly coordinated and complex process involving events ranging from neurulation, proliferation and differentiation of progenitor cells to migration, formation of synapse and neural circuits. The external signals such as morphogens and growth factors, activation of specific gene cascades and cellular interactions involved in the specification, differentiation and maturation of DAergic function have been discussed elsewhere (for extensive reviews see [6,7,8,9,10,11,12,13,14]). Impaired mesencephalic DA neurotransmission is involved in movement disorders, as well as selected psychotic syndromes. The alteration of motor control as a specific syndrome related to DA was described in 1817, by James Parkinson (1755–1824) in his milestones monograph “Essay on the Shaking Palsy” in London. However the disorder was known since antiquity and already treated with the seeds of a legume plant (Mucuna pruriens) that contains the therapeutic levels of what is now known as levodopa, used in Parkinson’s disease (PD) treatment. 1.1. What Is Dopamine? DA, also known as 3,4-dihydroxytyramine, is a neurotransmitter produced by DAergic neurons in the brain. DA is synthesized by the tyrosine hydroxylase enzyme, which, by adding a hydroxyl group, transforms tyrosine into L-DOPA, which in turn is decarboxylated into DA. The synaptic vesicle protein VMAT2 (vesicular monoamine transporter 2) carries DA into the vesicles, from which it is released into the synaptic cleft and binds to DARs. DA binds to five receptor subtypes: D1–D5, which are members of the G protein-coupled receptor family (GPCR), classified into two major subclasses: D1R-like and D2R-like receptor families. D1R-like receptors (D1R and D5R) generally couple to the Gs/olf proteins that stimulate adenylate cyclase (AC), the enzyme that converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP) and consequently increase cAMP production. The latter activates protein kinase A (PKA), which in turn phosphorylates c-AMP response element-binding protein (CREB), which is translocated into the nucleus activating CREB-dependent transcription of genes involved in synaptic plasticity. D1R modulate different ion channels, including voltage-activated Na+, K+, Ca2+ channels and G-protein gated inwardly rectifying K+ (GIRK) channel [15,16,17,18]. Conversely, D2R-like receptors (D2R, D3R and D4R) by coupling to Gi/o proteins, induce inhibition of AC and PKA-dependent pathways, as well as activation of GIRK and closure of voltage-activated Ca2+ channels [19]. DA receptors can act as monomers or as dimeric and/or oligomeric complexes by association of different subtypes, either alone or with other GPCRs and ligand-gated channels. D1R-D2R, D2R-D4R, D1R-D3R, D2R-D3R and D2R-D5R exist as homodimers. Oligomeric complexes contain DA receptors associated to the adenosine A1 and A2, serotoninergic 5-HT2A, histaminergic H3, glutamatergic mGlu5 and NMDA receptors [20]. Dimeric/oligomeric complexes display pharmacological and functional properties distinct from their constituent receptors. DA receptors can also activate G proteins independent mechanisms. The latter is mediated by the multifunctional adaptor protein arrestin, which binds DA receptors phosphorylated by GPCR kinases (GRKs; [21]) and recruits several proteins, including Akt, GSK-3, MAPK, c-Src, Mdm2 and N-ethylmaleimide-sensitive factor [22]. Arrestin binding to active phosphorylated receptors stops further G protein activation and promotes receptor endocytosis. There are seven GRKs in mammals: GRK2, GRK3, GRK4, GRK5 and GRK6 regulate D1R and D2R [23,24,25,26], whereas GRK4 controls D3R [25]. The striatum expresses GRKs 2, 3, 5, and 6 with different expression levels and cellular and subcellular distribution [27]. Therefore, DA is either excitatory or inhibitory depending on which receptors are found on the surface of the target neuron’s membrane and how these neurons respond to the increase or decrease in cAMP concentration. Thus, different functional roles of DA are to be expected that depend on receptor subtype, cell type, synaptic properties, and interactions with other transmitters. 1.2. The Mesencephalic Dopaminergic System Since the middle of the last century it has been understood that the DAergic system has also a fundamental importance in behavioral control and that its dysfunctions generate serious neurological and psychiatric diseases. Its involvement in the orchestration of the neural mechanisms of learning and memory to the pursuit of rewards and the clues behind them is essential for survival behaviors [28]. The stimuli that produce motivation and reward (sex, food, water, drugs, listening to music), increase the release of DA. DA neurotransmission plays a central role also in working memory, the ability to retain information for short periods of time, by changing the density of D1 receptors in the prefrontal cortex (PFC) [29]. In the mammalian central nervous system, three large neural circuits are controlled by SN and VTA mDAergic neurons: the nigrostriatal, the mesolimbic, and the mesocortical pathways (Figure 1). [Figure: A simplified schematic of the major connections to and from the ventral tegmental area (VTA) and substantia nigra (SN) in the rodent brain. The primary reward circuit includes DAergic projections from the VTA to the nucleus accumbens (nAc), which release dopamine (DA) in response to reward-related stimuli. The nAc receives dense innervation from glutamatergic neurons from the medial prefrontal cortex (mPFC), hippocampus (Hipp) and amygdala (Amy), as well as other regions (Lateral Hypothalamus, LH). The caudate and putamen nuclei of striatum receive dense innervation from zona compacta of the SN and from PFC. The DAergic pathways control attention, addiction, reward,